( Pharmacokinetic and Safety Profile of t...)BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference,Health

BIRMINGHAM, Ala., June 18, 2007 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. presented results from two Phase I clinical studies of an intramuscular (i.m.) formulation of peramivir at the Options for the Control of Influenza Conference in Toronto, Ontario, Canada. This major international influenza conference is held only once every four years.

These studies represent an important component of the company's clinical development program for peramivir, a neuraminidase inhibitor being developed for the treatment of seasonal and potentially life-threatening influenza. Top-line data are summarized as follows:

    -- A total of 51 healthy adult volunteers received either one of three

       dose regimens of peramivir or placebo

    -- Maximum plasma concentrations of peramivir (ranging from approximately

       4,000 ng/mL to 15,000 ng/mL) were present as early as 20 minutes after

       administration

    -- Peramivir exhibited a long terminal half-life (17.7 to 24.3 hours)

    -- The bioavailability of single doses of i.m. peramivir is high (>98%)

    -- Peramivir was well-tolerated in both of these studies

Jon P. Stonehouse, Chief Executive Officer of BioCryst said "these findings suggest an excellent safety profile of peramivir when given as an intramuscular injection, and, secondly, the concentrations of peramivir in blood after intramuscular dosing are reassuringly high and are similar to levels after intravenous administration. We look forward to the completion of our ongoing Phase II study of i.m. peramivir in the treatment of acute influenza in outpatients."

BioCryst is advancing the clinical development of peramivir under terms of a contract from the U.S. Department of Health and Human Services (DHHS) which on Janu
'"/>